New hope for rare leukemia: drug cocktail shows promise
NCT ID NCT06991920
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of two newer drugs, blinatumomab and venetoclax, along with standard chemotherapy, for adults with a rare type of leukemia called acute leukemia of ambiguous lineage (ALAL). The goal is to see if this approach improves survival and remission rates. The trial will enroll 50 participants across multiple centers in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
blinatumomab and venetoclax
What this could lead to
If successful, this combination could become a standard first-line treatment for this rare leukemia, improving survival and remission rates.
What could go wrong
This is a small, early-phase trial with no control group, so results may not be definitive. The drugs can cause serious side effects like infections and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE UNDIFFERENTIATED LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••